Antidiabetics market seen reaching $141.48 billion by 2030

The global antidiabetics market is projected to grow from $93.29 billion in 2026 to $141.48 billion by 2030, according to The Business Research Company. Growth is tied to rising diabetes prevalence, broader treatment options and increasing use of GLP-1 and SGLT2 drugs.

Why it matters: - The antidiabetics market is expanding as diabetes rates rise worldwide and demand grows for treatments that manage blood sugar, reduce complications and support broader metabolic health. - The market’s growth reflects a shift toward newer therapies, including once-weekly and long-acting drugs, that may improve adherence and patient outcomes.

What happened: - The Business Research Company said the antidiabetics market is expected to rise from $84.07 billion in 2025 to $93.29 billion in 2026, a compound annual growth rate of 11.0%. - The market is projected to reach $141.48 billion by 2030, while maintaining an 11.0% CAGR. - The company published a free sample of the report here. - The full report is available here.

The details: - Antidiabetics are drugs used to treat diabetes mellitus, a condition marked by elevated blood sugar. - The medications help regulate glucose through different mechanisms based on diabetes type and drug action. - The drugs are used to manage blood sugar, reduce disease complications, improve metabolic control and insulin sensitivity, and support customized treatment plans. - Many antidiabetic drugs also support weight management and cardiovascular protection. - The historical growth drivers include rising diabetes prevalence, wider insulin access, more oral antidiabetic options, stronger disease awareness and diagnosis, and better access to healthcare. - Future growth is expected to come from adoption of next-generation diabetes drugs, more long-acting and once-weekly therapies, digital diabetes management tools, increased research into metabolic disorders and demand for patient-centric care. - Key trends expected to shape the market include more use of GLP-1 and SGLT2 therapies, combination drug regimens, personalized diabetes care, growth in oral antidiabetic drugs, and greater focus on cardiovascular and weight-management benefits. - North America was the largest regional market in 2025. - The report also covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

Between the lines: - Lifestyle-related health issues are adding to demand for antidiabetic drugs, especially conditions linked to poor diet, sedentary behavior, smoking and excessive alcohol intake. - The report uses Canadian cigarette production as an example of persistent lifestyle risk factors, citing Statistics Canada data showing manufacturers produced 1.2 billion cigarettes in July 2024, up 4.3% from June 2024 and 2.3% from July 2023. - The market outlook suggests diabetes care is moving beyond glucose control toward therapies that also address weight and cardiovascular risk.

What's next: - The market is expected to keep growing as drug makers push newer therapies and as digital tools become more embedded in diabetes care. - The Business Research Company said its 2026 market reports include market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, plus updated graphics and tables. - The company also provided contact details for expert inquiries and promoted its LinkedIn presence.